Development of therapeutics designed to inhibit BCR-ABL such as tyrosine kinase inhibitors (TKIs) Imatinib and Dasatinib has improved the therapy of CP-CML; however, the emergence of leukemic stem cell (LSC) clones eventually relapse and succumb to the disease in CML patients in AP or BP (Chorzalska et al., 2018[12]). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.